At the news
? NEUTRALIMPACT 2/10 PRESS-RELEASE filed Apr 3, 2026 at 08:30 ET
Bicara Therapeutics granted a stock option to purchase 44,175 shares to a new employee as an inducement to join the company. The award was made outside of its shareholder-approved plans under the 2026 Inducement Plan, consistent with Nasdaq rules.
- Bicara Therapeutics granted a non-qualified stock option to purchase 44,175 shares to a new employee on April 1, 2026.
- The option has an exercise price of $20.50 per share, equal to the closing price on the grant date.
- Vesting: 25% on first anniversary, remaining 75% over 12 equal quarterly installments.
- Grant made under the 2026 Inducement Plan, approved by independent directors, outside shareholder-approved equity plans.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access